Optimizing Drug Discovery And Development Collaborations

By Ramesh Mullangi, LAXAI

Drug developers seeking a contract research organization (CRO) with whom to partner face an exhaustive list of challenges. In addition to finding a partner whose size is a good fit and whose availability aligns with their own timelines, the drug developer must deep-dive into the CRO’s capabilities — both those they expect to need and those that may become necessary unexpectedly.

Additionally, drug developers are well-served by working with a CRO partner that prioritizes knowledge creation and retention within the CRO for the benefit of the client, versus a more transactional approach. As demand for more precise, tailored CRO services grows, so too does the emphasis drug developers place on their partners’ flexibility, agility, and enthusiasm for collaboration (versus a more rigid “take-it-or-leave-it” approach to services).

LAXAI has developed a new partnered engagement model that implements unique full-time equivalent (FTE) arrangements to achieve customers’ specific short-term and long-term goals. Thus, the aim is not only to provide (and maintain) an ever-improving knowledge and experience base rooted in the continuity of resources — leading to consistent high-end services — but also to provide a transparent, comprehensive partnership experience for our customers.